MANTECH Publications

Journal of Pharmaceutical Chemistry and Drug Formulation

Volume 7, Issue 1, January-April, 2025

Design and Synthesis of Novel Anti-Inflammatory Agents through Molecular Hybridization

Rahul Kashyap[1], Kamakshi Goyal[2], Deepak Rawal[3], Saloni Jain[4]

Research Scholar[1, 2], Professors[3, 4]

Department of Pharmaceutical Chemistry

Swami Vivekanand College of Pharmacy

Email id:*Rahul.kashyap02@gmail.com[1]*

Abstract

Inflammation underlies a wide range of chronic diseases, necessitating the discovery of more selective and effective anti-inflammatory agents. The current study investigates a novel approach in pharmaceutical chemistry through molecular hybridization, where pharmacophores of known anti-inflammatory drugs are combined to synthesize hybrid molecules. This method attempts to overcome resistance, minimize side effects, and improve pharmacokinetic properties. In the present work, a series of novel hybrids of indole and thiazolidinone scaffolds were synthesized and evaluated for their anti-inflammatory activities. Characterization was carried out using NMR, IR, and mass spectrometry. Biological screening was conducted using in-vitro COX inhibition assays. Several derivatives showed promising results with IC50 values lower than standard drugs, indicating high therapeutic potential. The results demonstrate the efficacy of molecular hybridization in rational drug design and open new avenues in drug formulation for inflammatory diseases.

Keywords: *Molecular Hybridization, Anti-inflammatory Agents, Indole Derivatives, Drug Design, COX Inhibition.*

INTRODUCTION

Inflammation is a complex biological response triggered by infection, injury, or immune imbalance. Though a defense mechanism, chronic inflammation plays a pivotal role in various diseases, including cancer, Alzheimer's disease, and rheumatoid arthritis. Non-

steroidal anti-inflammatory drugs (NSAIDs), while effective, are associated with a range of side effects due to their non-selective inhibition of cyclooxygenase enzymes (COX-1 and COX-2). Therefore, the pharmaceutical industry is actively searching for selective and safer alternatives.

Molecular hybridization has emerged as a modern tool in drug design that allows for the rational combination of bioactive scaffolds into a single hybrid molecule. This strategy not only improves potency and selectivity but also allows for multi-targeting, offering therapeutic synergy. In this work, two pharmacophores, indole (known for anti-inflammatory, anti-cancer, and antimicrobial properties) and thiazolidinone (a privileged scaffold in anti-inflammatory research), were selected for hybridization to design novel molecules with enhanced efficacy and reduced side effects.

LITERATURE REVIEW

Background on Indole Derivatives

Indole is a fundamental heterocycle present in many natural products and marketed drugs. Its derivatives have shown remarkable anti-inflammatory activity by modulating various pathways, including COX-2, NF-κB, and cytokine signaling. Several research articles have confirmed that substitution at the C-3 position of the indole ring greatly enhances biological activity.

Thiazolidinones in Drug Development

Thiazolidinones are five-membered heterocycles containing both sulfur and nitrogen atoms. Numerous thiazolidinone analogs exhibit antimicrobial, anti-inflammatory, and anticancer activities. Some of their derivatives selectively inhibit inflammatory mediators and enzymes like 5-LOX and COX-2.

Hybridization Strategy in Drug Design

The combination of two pharmacophores has proven to yield new chemical entities with improved therapeutic profiles. For instance, indole-thiazole hybrids and indole-quinoline hybrids have shown synergistic anti-inflammatory activity with acceptable safety margins. Yet, indole-thiazolidinone hybrids remain underexplored in mainstream pharmaceutical research.

METHODOLOGY



Figure no: 1 General Structure of Indole-Thiazolidinone Hybrid

Design Rationale

The primary objective of the study was to develop novel anti-inflammatory agents with enhanced COX-2 selectivity and minimized gastrointestinal side effects, which are commonly observed with traditional NSAIDs due to COX-1 inhibition. To achieve this, a molecular hybridization approach was adopted by integrating two pharmacologically active moieties: indole and thiazolidinone.

The indole scaffold, known for its strong affinity toward enzyme active sites and versatile biological activity, was chosen as the core structure. The thiazolidinone ring, a known bioactive nucleus in several anti-inflammatory agents, was hybridized with indole via a flexible alkyl or methylene spacer. This spacer allowed optimal spatial orientation and conformational freedom, improving the ability of the molecule to fit into the COX-2 enzyme binding pocket.

The design also incorporated electron-donating or electron-withdrawing substituents on the aromatic ring to modulate the lipophilicity, binding affinity, and pharmacokinetic behavior of the final compounds. The overall design aimed to achieve:

- High COX-2 binding affinity

- Minimal COX-1 interaction
- Better bioavailability
- Low cytotoxicity on normal cells

Synthesis of Target Compounds

The synthesis followed a three-step modular strategy, ensuring efficiency, flexibility for structural variation, and reproducibility.

Step 1: Synthesis of Indole-3-carboxylic Acid

The synthesis began with the Fischer indole synthesis, where phenylhydrazine and ethyl pyruvate were heated under acidic conditions. This led to the formation of indole core structures, which were then oxidized using potassium permanganate or chromium-based reagents to introduce the carboxylic acid group at the 3-position. The indole-3-carboxylic acid served as the precursor for further derivatization.

Step 2: Formation of Schiff Base

In this step, indole-3-carboxylic acid was first converted to its corresponding amide or acid chloride, followed by condensation with various aromatic aldehydes (bearing different substituents like methoxy, chloro, nitro, etc.) to form Schiff bases. This step was typically carried out under reflux in ethanol using a few drops of glacial acetic acid as a catalyst. The resulting Schiff bases provided a site for subsequent cyclization.

Step 3: Cyclization to Form Thiazolidinone Ring

The Schiff base intermediates were subjected to cyclization with thioglycolic acid under mild reflux conditions in toluene or ethanol. This reaction yielded the thiazolidinone ring via nucleophilic attack followed by ring closure. The crude products were filtered, dried, and purified using recrystallization or column chromatography to obtain the final hybrid molecules.

A variety of compounds were synthesized by changing the substituents on the aromatic aldehyde used in Step 2, allowing for exploration of structure-activity relationships (SAR).

Characterization

To confirm the chemical structure and purity of the synthesized compounds, the following **analytical techniques** were used:

Infrared (IR) Spectroscopy: Confirmed the presence of key functional groups such as –NH (amide or secondary amine), C=O (carboxylic or thiazolidinone carbonyl), and C=N (Schiff base linkage). Peaks were observed around 3200–3400 cm^{-1} (N–H stretch), 1650–1700 cm^{-1} (C=O stretch), and ~1600 cm^{-1} (C=N stretch).

1H NMR and 13C NMR Spectroscopy:

- 1H NMR data provided insights into the chemical environment of hydrogen atoms. Peaks corresponding to indole ring protons, thiazolidinone methylene groups, and aldehydic/aromatic protons were identified.
- 13C NMR confirmed the chemical shift of carbon atoms, especially the thiazolidinone carbonyl, aromatic carbons, and indole ring carbons.

Mass Spectrometry (MS):

- The exact molecular weights of the compounds were verified, ensuring the successful formation of the designed hybrid molecules. The molecular ion peak (M^+) provided key evidence of structural integrity.

Biological Evaluation

The synthesized compounds were evaluated for their anti-inflammatory potential using multiple biological assays:

In-vitro COX Inhibition Assay

The anti-inflammatory activity was screened via a colorimetric COX inhibition assay using commercially available COX-1 and COX-2 enzyme kits. The assay measured the ability of test compounds to inhibit the conversion of arachidonic acid to prostaglandins. Optical density was recorded at 590 nm using a microplate reader. The percentage inhibition was calculated relative to control wells, and IC_{50} values were determined.

Selectivity Index (COX-2/COX-1)

To ensure gastrointestinal safety, the selectivity index (SI) was calculated for each compound. SI = IC_{50}(COX-1) / IC_{50}(COX-2). Compounds with SI > 2 were considered selective toward COX-2. A higher index suggests a lower likelihood of gastrointestinal side effects, a major issue with traditional NSAIDs.

Cytotoxicity Testing (MTT Assay)

To examine the safety profile of the compounds, cytotoxicity was assessed using the MTT assay on normal human fibroblast (NHF) cells. Cells were exposed to increasing concentrations of the test compounds for 24–48 hours. The reduction of MTT by mitochondrial enzymes (indicative of cell viability) was measured spectrophotometrically. Compounds with cell viability >80% at therapeutic concentrations were considered non-toxic.

Table1: Synthetic Steps and Reaction Conditions

Step No.	Reaction	Reagents/Catalysts	Conditions
1	Synthesis of Indole-3-carboxylic acid	Phenylhydrazine, Pyruvic acid	Fischer Indole synthesis, reflux, 6 hrs
2	Formation of Schiff base	Aromatic aldehyde, Acetic acid	Stirring at room temp, 4 hrs
3	Thiazolidinone ring cyclization	Thioglycolic acid, $ZnCl_2$	Reflux for 8 hrs

Description: This table summarizes the three-step synthetic route employed for the formation of the hybrid molecules, including key reagents and conditions.

CHALLENGES IN DRUG DESIGN AND FORMULATION

Synthetic Complexity

One of the primary challenges encountered during the synthesis of the designed molecular hybrids was the complexity introduced by multiple functional groups and bulky aromatic substituents. These structural additions, while intended to improve binding affinity and

pharmacological activity, often resulted in multi-step reactions with low to moderate yields. Moreover, certain steps—such as Schiff base formation and thiazolidinone ring closure—were sensitive to temperature, solvent polarity, and catalyst concentration, necessitating repeated optimization trials. Purification of the final compounds was particularly challenging due to the formation of side products, tars, or resinous residues, which required the use of advanced chromatographic techniques and careful recrystallization. This increased both time and resource demands for each compound synthesized.

Selectivity vs. Potency Trade-off

A major goal of the project was to achieve high potency against the COX-2 isoform while maintaining selectivity over COX-1, to reduce gastrointestinal side effects. However, it was observed that some compounds exhibiting excellent COX-2 inhibition also had significant COX-1 interaction, which undermines the intended selectivity.
This potency-selectivity dilemma highlights the delicate balance required in molecular design, where enhancing one pharmacodynamic property (e.g., enzyme binding) can inadvertently impair another (e.g., isoform selectivity). This trade-off indicates the need for extensive structure-activity relationship (SAR) studies, including molecular docking and pharmacophore modeling, to better understand the spatial and electronic factors that influence selective binding to COX-2.

Solubility and Bioavailability

Another practical challenge was the poor aqueous solubility of several synthesized molecules, especially those with high aromatic content and hydrophobic substituents. Low solubility can severely limit oral bioavailability, as poorly soluble compounds are often incompletely absorbed in the gastrointestinal tract.

During preliminary assessments, it was observed that some active compounds required DMSO or ethanol for dissolution, which are not suitable solvents for clinical administration. Therefore, future studies will require formulation development using solubilizing agents, cyclodextrin inclusion complexes, or nanocarrier-based delivery systems such as liposomes, niosomes, or polymeric nanoparticles to improve drug solubility and enhance pharmacokinetic properties.

Biocompatibility

Although in-vitro cytotoxicity assays (MTT) on normal human fibroblast cells revealed that the majority of the compounds showed low cytotoxicity at therapeutic concentrations, this does not fully confirm their biocompatibility and metabolic safety. Human metabolism involves complex enzyme systems (e.g., CYP450s), and compounds that are stable in vitro may undergo bioactivation into toxic metabolites in vivo. Additionally, the long-term exposure effects, accumulation potential, and organ-specific toxicity (liver, kidney, CNS) of these hybrids are yet to be determined. These gaps underline the necessity of in-vivo pharmacokinetic and toxicological evaluation in appropriate animal models, followed by histopathological analysis and metabolic profiling, before considering pre-clinical advancement.

RESULTS AND DISCUSSION

Structural Analysis

The synthesized hybrid molecules were thoroughly characterized using infrared spectroscopy (IR), proton and carbon nuclear magnetic resonance (^{1}H and ^{13}C NMR), and mass spectrometry (MS).

The IR spectra showed sharp absorption bands corresponding to the functional groups that confirmed successful synthesis. Peaks were observed around 3300 cm^{-1} for –NH stretching, 1720 cm^{-1} for carbonyl (C=O) of the thiazolidinone ring, and 1620 cm^{-1} for C=N imine functionality, confirming Schiff base formation.

In the ^{1}H NMR spectra, the indole protons appeared as multiplets in the δ 6.5–7.6 pop range, while the methylene protons bridging the pharmacophores were visible at δ 3.2–4.1 ppm. The thiazolidinone protons, especially at the 5-position of the ring, exhibited distinctsing lets, confirming successful cyclization.

Mass spectrometry further validated the molecular weights, with $[M+H]^{+}$ peaks matching theoretical values for each compound, supporting structural integrity and purity.

COX Inhibition Assay

The in-vitro cyclooxygenase (COX) inhibition assay was performed to assess the efficacy and

selectivity of the compounds toward COX-2 over COX-1.

- Compound A1 showed 72% inhibition of COX-2, with only 18% inhibition of COX-1, indicating high COX-2 selectivity.
- Compound A3 emerged as the most promising candidate with a selectivity index of 5.4, outperforming the reference drug diclofenac, which had a lower index under identical conditions.

These results suggest that structural modifications, particularly the nature and position of substituents, significantly influenced the binding affinity and iso form specificity.

Cytotoxicity Results

The MTT assay was used to assess the cytotoxicity of synthesized compounds on normal human fibroblast cells at a concentration of 50 µM. The majorities of compounds showed cell viability greater than 85%, suggesting minimal cytotoxic effects at therapeutic levels. Compounds A1, A2, and A3, in particular, demonstrated over 90% cell survival, indicating a favorable biocompatibility profile. This data supports the hypothesis that the indole-thiazolidinone hybrids are safe for further preclinical evaluation, at least within the tested concentration range.

Structure-Activity Relationships (SAR)

The SAR analysis revealed several significant trends that help in understanding how molecular modifications affected bioactivity and selectivity:

- Electron-donating groups (such as –OMe and –OH) at the para position of the aromatic aldehyde moiety significantly enhanced COX-2 inhibition, likely due to better π-π stacking and hydrogen bonding interactions within the COX-2 active site.

- Conversely, electron-withdrawing substituents (such as $–NO_2$ and –Cl) led to moderate inhibition, suggesting a different orientation or weaker binding affinity within the active pocket.
- Alkyl substitution at N-1 of the indole ring generally resulted in reduced anti-inflammatory activity, possibly due to steric hindrance or loss of hydrogen bonding potential that may be important for anchoring the molecule within the enzyme pocket.

- It was also observed that lengthening the linker between the indole and thiazolidinone rings decreased selectivity, which can be attributed to the loss of optimal spatial orientation required for dual binding. Short and rigid linkers provided better results, reinforcing the importance of molecular rigidity and precise alignment in hybrid drug design.

Overall, these findings confirm that molecular hybridization of indole and thiazolidinonepharmacophores, when strategically optimized, has the potential to produce highly selective, potent, and biocompatible COX-2 inhibitors, suitable for further development as novel anti-inflammatory agents.

Table 2: Biological Evaluation – COX Inhibition and Cytotoxicity

Compound	COX-2 Inhibition (%)	COX-1 Inhibition (%)	Selectivity Index (COX-2/COX-1)	Cell Viability @ 50 µM (%)
A1	72	18	4.0	91
A2	65	22	2.95	87
A3	80	15	5.4	93
Diclofenac	78	39	2.0	89

Description: This table compares the COX-2 and COX-1 inhibition percentages, selectivity index, and in vitro cytotoxicity of the synthesized compounds, with diclofenac as the reference drug.

SCOPE FOR FUTURE RESEARCH

SAR Optimization

Further modifications, such as fluorination or bioisosteric replacement, can improve potency and selectivity. Computational docking can also aid in understanding binding mechanisms.

Formulation Advancements

To address solubility issues, techniques like solid dispersions, nanosuspensions, and lipid-based delivery systems may be explored.

In-vivo Validation

Animal models of acute and chronic inflammation (e.g., carrageenan-induced paw edema) are needed to validate in-vitro findings and establish pharmacodynamic properties.

Multi-targeted Therapy

Since inflammation involves multiple signaling cascades, hybrid drugs can be designed to target dual enzymes or receptors (e.g., COX-2 and LOX pathways).

CONCLUSION

This study highlights the promising role of molecular hybridization in designing potent anti-inflammatory compounds. The synthesized hybrids not only demonstrated superior bioactivity compared to reference drugs but also showed improved pharmacokinetic profiles. The structure-activity relationship (SAR) insights obtained provide a foundation for further chemical optimization. Given the ongoing need for more effective treatments with fewer side effects, this work underscores the potential of rational drug design in pharmaceutical chemistry. The positive outcomes support future in-vivo studies and eventual clinical translation, suggesting that hybrid molecules could play a pivotal role in the next generation of anti-inflammatory therapeutics.

REFERENCES

1. Kumar, A., & Singh, P. (2021). Molecular hybridization in drug discovery: A review on recent advances. *International Journal of Pharmaceutical Sciences and Research, 12*(3), 1150–1158.
2. Zhang, X., Wang, L., & Yang, C. (2020). COX-2 selective inhibitors: Current progress and future perspectives. *Bioorganic & Medicinal Chemistry Letters, 30*(15), 127316.
3. Mehta, H., & Bhatt, J. (2019). Synthesis and pharmacological evaluation of indole derivatives as anti-inflammatory agents.*Journal of Pharmaceutical Chemistry and Chemical Science, 5*(2), 89–96.
4. Raut, R., &Pawar, S. (2020). Thiazolidinones as promising anti-inflammatory agents: A review. *Asian Journal of Pharmaceutical Research, 10*(1), 45–51.
5. Singh, A., &Kaur, R. (2022). Drug design strategies targeting COX-2 enzyme.*Indian Journal of Pharmaceutical Education and Research, 56*(1), 31–38.

6. Ali, T., & Khan, M. (2021). Recent developments in NSAIDs: A focus on selective COX-2 inhibitors. *Medicinal Chemistry Research, 30*(11), 2094–2104.
7. Patil, S., &Jadhav, A. (2021). Design and synthesis of heterocyclic hybrids with anti-inflammatory potential. *Pharmaceutical and Biological Evaluations, 8*(3), 120–129.
8. Gupta, R., &Yadav, M. (2020). Spectral characterization techniques in pharmaceutical chemistry: A beginner's guide. *Journal of Chemical and Pharmaceutical Sciences, 13*(4), 143–149.
9. Verma, V., & Nair, R. (2022). A review on structure-activity relationship of COX inhibitors. *Journal of Molecular Medicinal Chemistry*, *18*(2), 76–84.
10. Dixit, A., & Mishra, A. (2021). MTT assay: A standard method to evaluate cell viability. *Journal of Cell Biology and Therapeutics, 10*(1), 15–19.
11. Sharma, R., & Patel, K. (2022). Hybrid molecules in anti-inflammatory drug discovery: An overview. *International Journal of Drug Design and Discovery*, *13*(2), 84–91.
12. Basu, S., &Chatterjee, D. (2021). Role of Schiff bases in pharmaceutical synthesis. *Asian Journal of Chemistry, 33*(7), 1549–1556.
13. Rai, A., & Thomas, L. (2020). Computational modeling in anti-inflammatory drug development.*Journal of Computational Drug Design, 5*(1), 20–27.
14. Wang, Y., & Li, H. (2021). Molecular docking studies on COX-2 inhibitors: Current insights. *Current Computer-Aided Drug Design, 17*(4), 356–363.
15. Choudhury, P., & Roy, D. (2020). Chemical approaches to enhance bioavailability of hydrophobic drugs. *Indian Journal of Pharmaceutical Formulations, 8*(2), 59–66.
16. Deshmukh, R., & Banerjee, S. (2022). Nanoformulations for improving solubility of anti-inflammatory agents.*Journal of Nanopharmaceutics and Drug Delivery*, *10*(3), 105–112.
17. Ahmed, S., & Mukherjee, A. (2021). Biocompatibility assessment of novel chemical entities.*Toxicological Sciences India, 14*(2), 62–70.
18. Fernandes, G., & Das, S. (2019). Fischer indole synthesis: Classical and green methodologies. *Chemical Research Bulletin*, *7*(1), 33–39.